Research News and Research

RSS

KHN column: Why the health reform repealers are wrong

"The effort to repeal health care reform, all in one fell swoop, seems to be stalling. Instead, the opponents of reform are trying to dismantle it piece by piece. The latest effort came last week, when a group of Republicans in the Senate proposed abolishing the Independent Payment Advisory Board. And therein lies a lesson about the future of American health care--and the two different shapes it could take" (8/2).

2 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

RegeneRx Biopharmaceuticals, Inc. today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4, is essential to healthy heart development and embryonic survival.

2 Aug 2010

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response, intolerance or no response to Centocor Ortho Biotech's Remicade.

2 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

MannKind second-quarter total operating expenses decrease to $16.0 million

MannKind Corporation today reported financial results for the second quarter ended June 30, 2010.

2 Aug 2010

Explorys secures $2.55M Series B financing from Santé Ventures

Explorys Inc., the leader in cloud computing solutions for healthcare data management, analytics, and outcomes measurement has secured $2.55M Series B financing from Santé Ventures, with follow-on participation from Cleveland Clinic Innovations.

2 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

Life Technologies launches new assay to detect deadly strain of E. coli

Life Technologies, a provider of innovative life science solutions, announced at the International Association of Food Protection annual meeting the launch of the MicroSEQ E. coli O157:H7 assay, designed to detect the deadly strain of Escherichia coli (E. coli), using the company's industry-leading real-time PCR technology.

2 Aug 2010

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

Charles River Laboratories International, Inc. today reported its results for the second quarter of 2010. For the quarter, net sales were $292.1 million, a decline of 5.2% from $308.2 million in the second quarter of 2009. Foreign currency translation reduced the sales growth rate by 0.1%. A modest sales increase in the Research Models and Services segment was offset by lower sales for the Preclinical Services segment.

2 Aug 2010

First Edition: August 2, 2010

Today's headlines include news about a pre-recess Senate push to pass a state aid measure as well as a preview of a White House report to be issued today that predicts savings in the Medicare program.

2 Aug 2010

INEOS agrees to sell Global Films business to Bilcare AG

INEOS Group has today entered into a binding agreement for the sale of its Global Films business to Bilcare AG, one of the world's leading providers of research led packaging to the global pharmaceuticals industry, for approximately EUR100 million. The agreement brings together complimentary capabilities and synergy's of two leading global businesses.

2 Aug 2010

Research shows no link between CCSVI and development of multiple sclerosis

Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.

2 Aug 2010

Screening tool kit to measure public facilities

Denis Anson, M.S., O.T.R., director of research and development for the Assistive Technology Research Institute (ATRI) at Misericordia University, has worn a lot of different hats in his professional career.By utilizing the expertise he's acquired during his 30 years of practice and application of assistive technology and occupational therapy strategies, Anson has devised and brought to market the Americans with Disabilities Act — Compliance Assessment Toolkit or ADA-CAT to measure whether public facilities are in compliance with the federal law that was enacted 20 years ago.

2 Aug 2010

GRS announces Martin as European General Manager, Executive Vice President of Global Development

Global Research Services, LLC (GRS), an international cardiovascular clinical research organization (CRO) serving pharmaceutical, biotech and medical device companies with comprehensive clinical trial management services, announced today that Benoît Martin, a seasoned executive with more than a decade of leading international CRO business units, has been named as the European General Manager and Executive Vice President of Global Development.

2 Aug 2010

Financial shortcomings in healthcare industry declines DR, CR purchase

Widespread capital freezes and financial shortcomings in the healthcare industry have caused a significant decline in the number of Digital Radiography (DR) and Computed Radiography (CR) purchases. One key challenge faced by the industry has been the lack of capital available for technologies which require high initial investments, such as digital solutions. However, with the economy recovering and funds becoming available to potential buyers, the unit shipment volume is expected to gain momentum in 2011.

2 Aug 2010

Nutritional labeling, point-of-purchase signs influence healthy food choices: Study

Poor diet and physical inactivity leading to obesity are poised to overtake tobacco use as the leading cause of preventable death in the United States. With over 30% of U.S. adults obese, the significant adverse health effects of obesity (including heart disease and diabetes) are widespread throughout the country. Two studies published in the August issue of the Journal of the American Dietetic Association shed light on behaviors regarding food choices and good nutrition and report on how nutritional labeling and point-of-purchase signs are influencing healthy food choices.

2 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Research News and Research

KHN column: Why the health reform repealers are wrong

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

MannKind second-quarter total operating expenses decrease to $16.0 million

Explorys secures $2.55M Series B financing from Santé Ventures

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

Life Technologies launches new assay to detect deadly strain of E. coli

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

First Edition: August 2, 2010

INEOS agrees to sell Global Films business to Bilcare AG

Research shows no link between CCSVI and development of multiple sclerosis

Screening tool kit to measure public facilities

GRS announces Martin as European General Manager, Executive Vice President of Global Development

Financial shortcomings in healthcare industry declines DR, CR purchase

Nutritional labeling, point-of-purchase signs influence healthy food choices: Study

Merck reports strong bottom-line performance in second quarter

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence